New advocacy resources to increase contraceptive access and choice with subcutaneous DMPA

PATH is pleased to launch the Advocacy Pack for Subcutaneous DMPA, a comprehensive suite of evidence-based tools that advocates can use to help increase access to a new type of injectable in their countries. 

Subcutaneous DMPA (DMPA-SC) is an innovative, easy-to-use injectable that is administered under the skin. It has the potential to dramatically increase contraceptive access by enabling community health workers to provide injections and even women to self-inject. DMPA-SC is currently being introduced or scaled in Family Planning 2020 (FP2020) countries as Pfizer’s branded product Sayana® Press.

The Advocacy Pack for Subcutaneous DMPA equips advocates with information, data, and tools to advance policy change and mobilize resources to support expanded access to this method, as part of a wide range of contraceptive options.

Advocacy pack highlights:

  • Available in English and French on the Reproductive Health Supplies Coalition website.
  • Consists of 15 tools to inform advocacy and communications planning and to support direct advocacy with decision-makers.
  • Based on the latest evidence on DMPA-SC.
  • Packaged as unbranded, customizable materials for country advocates and stakeholders.

Three ways to take action today: 

Thank you for your efforts to increase contraceptive access and choice for women and adolescent girls worldwide! Please send any questions or comments about these new resources to [email protected].

The Advocacy Pack for Subcutaneous DMPA was developed by PATH in collaboration with international and national family planning organizations. Capital for Good, a grant recipient of the Bill & Melinda Gates Foundation, provided generous support for this project.
Cliquez pour en savoir plus